1. Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study

   • Eric François
   • Jean-François Berdah
   • Véronique Mari

   Original Article 14 February 2008 Pages: 931 - 936

2. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo

   • Robert Mauritz
   • Godefridus J. Peters
   • Gerrit Jansen

   Original Article Open access 19 February 2008 Pages: 937 - 948

   

3. Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion

   • Zhigang Xie
   • Pei Feng Choong
   • Chien-Shing Chen

   Original Article 08 February 2008 Pages: 949 - 957

   

4. Th1/Th2 balance: an important indicator of efficacy for intra-arterial chemotherapy

   • Hidenari Nagai
   • Daisuke Miyaki
   • Kazumasa Miki

   Original Article 08 February 2008 Pages: 959 - 963

   

5. BRCA1 transcriptional activity is enhanced by interactions between its AD1 domain and AhR

   • Hyo Jin Kang
   • Hee Jeong Kim
   • Insoo Bae

   Original Article 08 February 2008 Pages: 965 - 975

   

6. Disruption of microfilaments by cytochalasin B decreases accumulation of cisplatin in human epidermal carcinoma and liver carcinoma cell lines

   • Xing-Jie Liang
   • Jun-Jie Yin
   • Adorjan Aszalos

   Original Article 15 February 2008 Pages: 977 - 984

   

7. Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model

   • Xianhua Cao
   • Guang Jia
   • Duxin Sun

   Original Article 06 February 2008 Pages: 985 - 994

   

8. Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapeutic activity

   • Noelle Callizot
   • Emile Andriambeloson
   • Michel Dreano

   Original Article 13 February 2008 Pages: 995 - 1007

   

9. Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer

   • Se Hoon Park
   • Eun Kyung Cho
   • Jae Hoon Lee

   Original Article 08 February 2008 Pages: 1009 - 1014

10. Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae

    • Min Huang
    • Jing Jin
    • Geng Tao Liu

    Original Article 13 February 2008 Pages: 1015 - 1026

    

11. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children’s oncology group

    • Patrick A. Thompson
    • Manish Gupta
    • John Mondick

    Original Article 16 February 2008 Pages: 1027 - 1037

    

12. Topotecan distribution in an anephric infant with therapy resistant bilateral Wilms tumor with a novel germline WT1 gene mutation

    • Rieneke T. Lugtenberg
    • Karlien Cransberg
    • Marry M. van den Heuvel-Eibrink

    Original Article Open access 14 February 2008 Pages: 1039 - 1044

    

13. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo

    • Terence O’Reilly
    • Markus Wartmann
    • Paul M. J. McSheehy

    Original Article 27 February 2008 Pages: 1045 - 1054

    

14. Inducing apoptosis and enhancing chemosensitivity to Gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell

    • San-Hua Wei
    • Ke Dong
    • Hui-Zhong Zhang

    Original Article 23 February 2008 Pages: 1055 - 1064

    

15. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor

    • Feng (Roger) Luo
    • Yu Chen Barrett
    • Francis Y. Lee

    Original Article Open access 27 February 2008 Pages: 1065 - 1074

    

16. Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms

    • Albert Font
    • Ramon Salazar
    • Rafael Rosell

    Original Article 12 March 2008 Pages: 1075 - 1083

    

17. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer

    • M. Ruiz
    • J. Salvador
    • A. Lopez-Ladrón

    Original Article 26 March 2008 Pages: 1085 - 1090

18. Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusion

    • Alan P. Brown
    • Cynthia L. Courtney
    • Bart A. Jessen

    Original Article 29 May 2008 Pages: 1091 - 1101

    

19. A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer

    • Akihiro Nakajo
    • Shuichi Hokita
    • Kyushu Taxol, TS-1, Study Group (KTT-SG)

    Clinical Trial Report 04 March 2008 Pages: 1103 - 1109

    

20. Tumor resensitization to erlotinib following brief substitution of cetuximab

    • R. J. Epstein
    • T. W. Leung

    Short Communication 19 February 2008 Pages: 1111 - 1112

    

21. Is oncogenesis a normal cellular defense mechanism?

    • Steven Sorscher
    • Aubrey E. Hill
    • Eric J. Sorscher

    Letter to the editor 15 February 2008 Pages: 1113 - 1113

22. Professor Lloyd R. Kelland: man of science

    • Herbie Newell
    • Mark McKeage
    • Clive Stanway

    Obituary 27 August 2008 Pages: 1115 - 1116